Photo by nci from unsplash
With increasing therapeutic options available for advanced hepatocellular carcinoma (HCC), the timing and sequencing of locoregional and systemic therapy need to be re-examined. This is especially so for patients with… Click to show full abstract
With increasing therapeutic options available for advanced hepatocellular carcinoma (HCC), the timing and sequencing of locoregional and systemic therapy need to be re-examined. This is especially so for patients with intermediate HCC, so as to optimize responses while preserving liver reserves, and in so allowing our patients to achieve the best survival outcomes possible.
Keywords:
hepatocellular carcinoma;
therapy hepatocellular;
carcinoma start;
locoregional therapy;
start stop;
therapy
Journal Title: ESMO Open
Year Published: 2021
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: ESMO Open
Year Published: 2021
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!